Skip to main content
Simcere Pharmaceutical Group Limited logo

Simcere Pharmaceutical Group Limited — Investor Relations & Filings

Ticker · S2P ISIN · HK0000658531 HKEX Manufacturing
Open in API
Filings indexed 577 across all filing types
Latest filing 2023-01-18 Board/Management Inform…
Country CN China
Listing HKEX S2P

About Simcere Pharmaceutical Group Limited

https://www.simcere.com/en/

Simcere Pharmaceutical Group Limited is an R&D-driven pharmaceutical company specializing in the discovery, development, and commercialization of innovative and branded generic prescription drugs. The company strategically focuses on core therapeutic areas, including neuroscience, anti-oncology, and inflammatory diseases. Simcere emphasizes synergistic innovation, evidenced by its development and launch of multiple Category I innovative pharmaceuticals and its strategic collaborations with global partners to advance novel treatments. These partnerships aim to address significant unmet medical needs and expand the company's portfolio across specialized disease areas.

Recent filings

Filing Released Lang Actions
LIST OF DIRECTORS AND THEIR ROLES AND FUNCTIONS
Board/Management Information Classification · 100% confidence The document is a list of directors and their roles and functions for Simcere Pharmaceutical Group Limited, including details about board committees and their members. It does not contain financial data, audit results, voting results, or any report content. It is an announcement related to the company's board structure and management roles. Therefore, it fits the category of Board/Management Information (MANG). The document length is short and focused solely on board composition, confirming this classification.
2023-01-18 English
POLL RESULTS OF THE EXTRAORDINARY GENERAL MEETING HELD ON JANUARY 18, 2023
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is an announcement from Simcere Pharmaceutical Group Limited regarding the poll results of an Extraordinary General Meeting (EGM) held on January 18, 2023. It details the voting outcomes on various resolutions including the grant of restricted share units (RSUs) to certain individuals and the appointment of an executive director and an independent non-executive director. The document includes detailed voting percentages and information about the directors' appointments and related shareholdings. There is no financial data or report content, but rather the official results of shareholder votes at the EGM. This matches the definition of 'Declaration of Voting Results & Voting Rights Announcements' (DVA). The document length is substantial and contains detailed voting results, not just a brief notice or a report publication announcement. Therefore, the correct classification is DVA with high confidence.
2023-01-18 English
VOLUNTARY ANNOUNCEMENT - NEW DRUG APPLICATION OF ANTI-SARS-COV-2 INNOVATIVE DRUG XIANNUOXIN (SIMNOTRELVIR TABLETS/RITONAVIR TABLETS (CO-PACKAGED)) ACCEPTED BY THE NATIONAL MEDICAL PRODUCTS ADMINI
Regulatory Filings Classification · 95% confidence The document is a voluntary announcement by Simcere Pharmaceutical Group Limited regarding the acceptance of a New Drug Application (NDA) by the National Medical Products Administration (NMPA) in China. It provides detailed information about the drug, clinical trials, and company background. There are no financial statements, earnings data, or regulatory filings related to financial performance. The document is an announcement of a business development event, specifically about drug approval progress, not a financial report or regulatory filing. It does not fit into categories like Annual Report, Earnings Release, or Regulatory Filings. It is a voluntary business update announcement, which aligns best with the category of Regulatory Filings (RNS) as a general announcement that does not fit other specific categories.
2023-01-16 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 December 2022
Regulatory Filings Classification · 95% confidence The document is titled 'Monthly Return for Equity Issuer and Hong Kong Depositary Receipts listed under Chapter 19B of the Exchange Listing Rules on Movements in Securities' for the month ended 31 December 2022. It details movements in issued shares, share options, warrants, convertibles, and other agreements related to share issuance. It is a regulatory submission to the Hong Kong Exchanges and Clearing Limited, reporting share capital and share movements for a specific month. The document does not contain financial statements or management discussion but is a regulatory filing about share capital movements. It is not an annual or interim report, earnings release, or any other financial report type. It fits best under Regulatory Filings (RNS) as a general regulatory announcement about share capital movements under exchange rules.
2023-01-05 English
CHANGE OF IMPORTANT EXECUTIVE FUNCTIONS OF DIRECTOR
Board/Management Information Classification · 100% confidence The document is an announcement from Simcere Pharmaceutical Group Limited regarding a change in executive functions of a director, specifically the resignation of Mr. Tang Renhong from the position of Co-CEO and his new appointment within a subsidiary. The content focuses on management changes and does not contain financial data, report publication, or voting results. The document length is short (2337 characters) and is clearly an announcement of management changes. Therefore, it fits the category of Board/Management Information (MANG).
2022-12-30 English
VOLUNTARY ANNOUNCEMENT - THE CLINICAL TRIAL APPROVAL FOR SIM0348 INJECTION (HUMANIZED TIGIT/PVRIG BISPECIFIC ANTIBODY) ISSUED BY THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION
Regulatory Filings Classification · 95% confidence The document is a voluntary announcement by Simcere Pharmaceutical Group Limited regarding the clinical trial approval for a new drug (SIM0348 injection) issued by the National Medical Products Administration. It is an announcement of a business development event, not a financial report or regulatory filing. The document is short (3499 characters) and does not contain financial data, audit information, management changes, or voting results. It is not a report but an announcement of a clinical trial approval, which fits best under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories.
2022-12-29 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.